Go Pro
→ Read now. Do not delete. You’ve been warned. (From Porter & Company) (Ad)tc pixel Free TNYA Stock Alerts

Tenaya Therapeutics (TNYA) Financials

Tenaya Therapeutics logo
$0.79 0.00 (0.00%)
Closing price 07/2/2026 04:00 PM Eastern
Extended Trading
$0.78 0.00 (-0.37%)
As of 07/2/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Tenaya Therapeutics

Annual Income Statements for Tenaya Therapeutics

This table shows Tenaya Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Net Income / (Loss) Attributable to Common Shareholders		 -38 -73 -124 -124 -111
Consolidated Net Income / (Loss)		 -38 -73 -124 -124 -111
Net Income / (Loss) Continuing Operations		 -38 -73 -124 -124 -111
Total Pre-Tax Income 		-38 -73 -124 -124 -111
Total Operating Income		 -39 -73 -126 -131 -116
Total Gross Profit		 0.00 0.00 0.00 0.00 0.00
Total Revenue		 0.00 0.00 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 39 73 126 131 116
Selling, General & Admin Expense		 7.81 18 31 33 29
Research & Development Expense		 31 54 95 98 87
Total Other Income / (Expense), net		 0.52 0.09 1.96 7.11 4.82
Interest & Investment Income		 0.09 0.11 1.95 7.06 4.74
Other Income / (Expense), net		 0.43 -0.02 0.00 0.05 0.08
Basic Earnings per Share		 ($39.50) ($4.10) ($2.76) ($1.68) ($1.31)
Weighted Average Basic Shares Outstanding		 972.09K 17.73M 44.82M 73.79M 84.82M
Diluted Earnings per Share		 ($39.50) ($4.10) ($2.76) ($1.68) ($1.31)
Weighted Average Diluted Shares Outstanding		 972.09K 17.73M 44.82M 73.79M 84.82M
Weighted Average Basic & Diluted Shares Outstanding		 972.09K 17.73M 66.87M 78.52M 87.58M

Quarterly Income Statements for Tenaya Therapeutics

This table shows Tenaya Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -29 -30 -32 -29 -26 -24 -27 -23 -20 -19
Consolidated Net Income / (Loss)		 -29 -30 -32 -29 -26 -24 -27 -23 -20 -19
Net Income / (Loss) Continuing Operations		 -29 -30 -32 -29 -26 -24 -27 -23 -20 -19
Total Pre-Tax Income 		-29 -30 -32 -29 -26 -24 -27 -23 -20 -19
Total Operating Income		 -31 -31 -34 -31 -27 -25 -28 -24 -21 -20
Total Gross Profit		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 0.23
Total Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 0.23
Operating Revenue		 - - - - - - - - - 0.23
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 0.00
Total Operating Expenses		 31 31 34 31 27 25 28 24 21 20
Selling, General & Admin Expense		 7.83 8.58 8.71 8.17 6.36 5.96 6.46 6.71 5.57 5.45
Research & Development Expense		 23 23 25 23 20 19 21 17 15 15
Total Other Income / (Expense), net		 1.78 1.51 1.53 1.39 1.08 0.82 0.67 0.80 0.66 0.79
Interest & Investment Income		 1.78 1.47 1.45 1.39 1.08 0.81 0.64 0.82 0.66 0.79
Other Income / (Expense), net		 0.00 0.04 0.08 -0.00 -0.00 0.00 0.04 -0.02 0.00 0.00
Income Tax Expense		 - - - 0.00 0.00 - 0.00 0.00 0.00 0.00
Basic Earnings per Share		 ($0.39) ($0.41) ($0.40) ($0.34) ($0.30) ($0.27) ($0.24) ($0.14) ($0.12) ($0.09)
Weighted Average Basic Shares Outstanding		 73.92M 73.79M 80.98M 85.71M 86.16M 84.82M 109.87M 162.79M 163.35M 216.88M
Diluted Earnings per Share		 ($0.39) ($0.41) ($0.40) ($0.34) ($0.30) ($0.27) ($0.24) ($0.14) ($0.12) ($0.09)
Weighted Average Diluted Shares Outstanding		 73.92M 73.79M 80.98M 85.71M 86.16M 84.82M 109.87M 162.79M 163.35M 216.88M
Weighted Average Basic & Diluted Shares Outstanding		 68.11M 78.52M 78.52M 78.89M 79.22M 87.58M 162.67M 162.98M 166.51M 217.00M

Annual Cash Flow Statements for Tenaya Therapeutics

This table details how cash moves in and out of Tenaya Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Net Change in Cash & Equivalents		 105 -90 57 -49 -42
Net Cash From Operating Activities		 -35 -61 -104 -102 -91
Net Cash From Continuing Operating Activities		 -35 -61 -104 -102 -91
Net Income / (Loss) Continuing Operations		 -38 -73 -124 -124 -111
Consolidated Net Income / (Loss)		 -38 -73 -124 -124 -111
Depreciation Expense		 2.48 2.96 6.47 8.69 8.47
Amortization Expense		 - 0.13 -0.31 0.32 -0.18
Non-Cash Adjustments To Reconcile Net Income		 0.70 4.08 14 19 16
Changes in Operating Assets and Liabilities, net		 -0.05 4.74 -0.85 -5.65 -3.81
Net Cash From Investing Activities		 -7.01 -239 84 49 1.13
Net Cash From Continuing Investing Activities		 -7.01 -239 84 49 1.13
Purchase of Property, Plant & Equipment		 -9.76 -25 -21 -1.24 -1.03
Purchase of Investments		 - -213 -140 -57 -87
Sale and/or Maturity of Investments		 2.75 0.00 245 107 89
Other Investing Activities, net		 - 0.00 0.01 -0.03 0.02
Net Cash From Financing Activities		 147 209 78 4.05 48
Net Cash From Continuing Financing Activities		 147 209 78 4.05 48
Repurchase of Common Equity		 -0.00 -0.01 0.00 -0.50 0.00
Issuance of Common Equity		 - 189 77 3.87 47
Other Financing Activities, net		 0.03 0.37 0.38 0.68 0.99

Quarterly Cash Flow Statements for Tenaya Therapeutics

This table details how cash moves in and out of Tenaya Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Net Change in Cash & Equivalents		 6.85 -36 14 -1.43 -50 -3.91 49 8.90 -6.36 -20
Net Cash From Operating Activities		 -24 -22 -29 -24 -20 -18 -23 -16 -16 -19
Net Cash From Continuing Operating Activities		 -24 -22 -29 -24 -20 -18 -23 -16 -16 -19
Net Income / (Loss) Continuing Operations		 -29 -30 -32 -29 -26 -24 -27 -23 -20 -19
Consolidated Net Income / (Loss)		 -29 -30 -32 -29 -26 -24 -27 -23 -20 -19
Depreciation Expense		 2.18 2.18 2.16 2.12 2.10 2.09 2.66 2.08 1.86 1.76
Amortization Expense		 -0.32 1.69 -0.07 0.14 -0.01 -0.24 0.03 0.27 0.11 0.00
Non-Cash Adjustments To Reconcile Net Income		 4.86 4.82 5.13 5.49 5.03 0.52 4.50 4.31 3.62 2.86
Changes in Operating Assets and Liabilities, net		 -1.22 -0.67 -3.64 -1.94 -1.32 3.08 -3.44 1.01 -0.92 -4.58
Net Cash From Investing Activities		 30 -15 -4.49 22 -30 14 22 25 8.86 -0.01
Net Cash From Continuing Investing Activities		 30 -15 -4.49 22 -30 14 22 25 8.86 -0.01
Purchase of Property, Plant & Equipment		 -0.01 -0.39 -0.56 -0.07 -0.18 -0.20 -0.38 -0.14 -0.03 -0.01
Sale and/or Maturity of Investments		 31 1.14 20 32 21 16 23 25 8.89 0.00
Net Cash From Financing Activities		 - 0.37 47 0.57 0.03 0.38 50 -0.48 0.38 -0.42
Net Cash From Continuing Financing Activities		 - 0.37 47 0.57 0.03 0.38 50 -0.48 0.38 -0.42
Repurchase of Common Equity		 - - - - - - 0.00 - - -0.42
Issuance of Common Equity		 - - 47 - - - 50 -0.55 - 0.00

Annual Balance Sheets for Tenaya Therapeutics

This table presents Tenaya Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 148 314 279 171 120 147
Total Current Assets		 130 255 194 112 67 106
Cash & Equivalents		 129 38 95 46 4.32 101
Short-Term Investments		 0.00 213 91 59 57 0.00
Accounts Receivable		 - - - - - 0.00
Prepaid Expenses		 1.43 4.06 7.23 6.94 5.93 5.04
Plant, Property, & Equipment, net		 17 43 51 43 36 28
Total Noncurrent Assets		 1.01 16 34 16 17 14
Other Noncurrent Operating Assets		 1.01 16 16 16 17 14
Total Liabilities & Shareholders' Equity		 148 314 279 171 120 147
Total Liabilities		 8.72 36 36 31 27 24
Total Current Liabilities		 5.04 22 24 23 16 15
Accounts Payable		 1.02 11 9.58 5.63 5.16 3.58
Accrued Expenses		 3.16 9.06 11 13 8.04 8.84
Current Deferred Revenue		 0.86 - - - - 0.00
Other Current Liabilities		 0.00 1.99 4.01 4.32 2.78 3.02
Total Noncurrent Liabilities		 3.68 14 11 8.36 11 8.22
Noncurrent Deferred Revenue		 3.66 - - - - 0.00
Other Noncurrent Operating Liabilities		 0.02 14 11 8.36 11 8.22
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -81 279 243 139 93 123
Total Preferred & Common Equity		 -81 279 243 139 93 123
Preferred Stock		 - - 0.00 0.00 - 0.00
Total Common Equity		 -81 279 243 139 93 123
Common Stock		 1.58 434 523 543 607 728
Retained Earnings		 -83 -156 -279 -403 -514 -605
Accumulated Other Comprehensive Income / (Loss)		 0.00 -0.14 -0.38 -0.11 0.03 0.00

Quarterly Balance Sheets for Tenaya Therapeutics

This table presents Tenaya Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 193 185 163 141 144 122 105 135
Total Current Assets		 127 129 105 85 94 76 61 97
Cash & Equivalents		 82 59 58 8.23 54 63 56 81
Short-Term Investments		 40 63 41 71 34 9.00 0.00 0.00
Accounts Receivable		 - - - - - - - 11
Prepaid Expenses		 5.08 6.45 5.73 5.86 6.33 4.21 4.93 5.05
Plant, Property, & Equipment, net		 45 41 39 38 33 31 29 26
Total Noncurrent Assets		 21 15 19 17 16 15 14 13
Other Noncurrent Operating Assets		 15 15 19 17 16 15 14 13
Total Liabilities & Shareholders' Equity		 193 185 163 141 144 122 105 135
Total Liabilities		 29 27 29 28 25 22 22 29
Total Current Liabilities		 19 19 17 16 14 13 13 17
Accounts Payable		 5.90 6.66 4.32 5.84 5.06 3.30 2.84 1.91
Accrued Expenses		 10 8.44 9.03 7.33 6.29 6.52 7.44 6.03
Current Deferred Revenue		 - - - - - - - 5.72
Other Current Liabilities		 3.15 4.06 3.36 3.01 2.79 2.83 2.93 3.12
Total Noncurrent Liabilities		 9.14 7.56 12 12 10 9.67 8.90 12
Noncurrent Deferred Revenue		 - - - - - - - 4.68
Other Noncurrent Operating Liabilities		 9.14 7.56 12 12 10 9.67 8.90 7.42
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 165 158 134 113 119 100 83 106
Total Preferred & Common Equity		 165 158 134 113 119 100 83 106
Preferred Stock		 - - - - - - - 0.00
Total Common Equity		 165 158 134 113 119 100 83 106
Common Stock		 538 594 599 603 661 664 668 730
Retained Earnings		 -373 -436 -465 -491 -541 -565 -585 -624
Accumulated Other Comprehensive Income / (Loss)		 -0.26 -0.12 -0.07 0.08 -0.01 -0.00 0.00 0.00

Annual Metrics And Ratios for Tenaya Therapeutics

This table displays calculated financial ratios and metrics derived from Tenaya Therapeutics' official financial filings.

Metric 2020 2021 2022 2023 2024
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Growth Metrics		 - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 0.00% -93.72% -71.30% -2.24% 11.92%
EBIT Growth		 0.00% -89.25% -72.48% -4.40% 11.65%
NOPAT Growth		 0.00% -87.10% -72.54% -4.44% 11.62%
Net Income Growth		 0.00% -89.40% -70.05% -0.34% 10.44%
EPS Growth		 0.00% 89.62% 32.68% 39.13% 22.02%
Operating Cash Flow Growth		 0.00% -71.56% -71.72% 2.25% 11.34%
Free Cash Flow Firm Growth		 0.00% 0.00% -48.40% 12.40% 11.07%
Invested Capital Growth		 0.00% 149.69% 43.78% -11.15% -9.70%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 0.00% 0.00% -6.72% 4.14% 4.22%
EBIT Q/Q Growth		 0.00% 0.00% -7.11% 2.34% 5.51%
NOPAT Q/Q Growth		 0.00% 0.00% -7.15% 2.31% 5.54%
Net Income Q/Q Growth		 0.00% 0.00% -6.33% 2.81% 5.20%
EPS Q/Q Growth		 0.00% 0.00% -114.09% 9.19% 9.66%
Operating Cash Flow Q/Q Growth		 0.00% -10.84% -6.46% 0.74% 3.76%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% -4.26% 5.47%
Invested Capital Q/Q Growth		 0.00% 0.00% -16.49% -5.39% -5.21%
Profitability Metrics		 - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 99.77% 99.85% 98.44% 94.62% 95.91%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -27.54% -34.80% -47.39% -64.83% -95.69%
Cash Return on Invested Capital (CROIC)		 0.00% -352.93% -300.89% -236.64% -235.05%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 16.06% -16.42% -47.39% -64.83% -95.69%
Return on Equity Simple (ROE_SIMPLE)		 47.22% -26.11% -50.81% -89.00% -119.68%
Net Operating Profit after Tax (NOPAT)		 -27 -51 -88 -92 -81
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -8.68% -11.46% -15.69% -20.88% -36.08%
Return On Investment Capital (ROIC_SIMPLE)		 - - - -65.87% -87.41%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -38 -73 -126 -131 -116
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -36 -70 -119 -122 -108
Valuation Ratios		 - - - - -
Price to Book Value (P/BV)		 0.00 2.81 0.34 1.58 1.22
Price to Tangible Book Value (P/TBV)		 0.00 2.81 0.34 1.58 1.22
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 22.21 19.50 0.00 3.34 1.65
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -0.92 -0.91 -0.87 -0.81 -0.72
Leverage Ratio		 1.06 1.11 1.14 1.17 1.25
Compound Leverage Factor		 1.06 1.10 1.12 1.11 1.20
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 158.32% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 -58.32% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 9.69 12.60 -0.76 -0.97 -6.17
Noncontrolling Interest Sharing Ratio		 158.32% 52.82% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - -
Current Ratio		 25.78 11.73 7.99 4.91 4.22
Quick Ratio		 25.50 11.54 7.69 4.60 3.85
Cash Flow Metrics		 - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -67 -100 -87 -78
Operating Cash Flow to CapEx		 -363.07% -242.08% -506.18% -8,238.26% -8,829.37%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - -
Invested Capital		 11 27 39 35 31
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 0.00 16 12 -4.36 -3.37
Enterprise Value (EV)		 242 531 -121 116 52
Market Capitalization		 150 782 83 221 113
Book Value per Share		 ($83.65) $6.75 $5.88 $2.05 $1.17
Tangible Book Value per Share		 ($83.65) $6.75 $5.88 $2.05 $1.17
Total Capital		 139 279 243 139 93
Total Debt		 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00
Net Debt		 -129 -251 -204 -105 -61
Capital Expenditures (CapEx)		 9.76 25 21 1.24 1.03
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -3.61 -18 -17 -16 -10
Debt-free Net Working Capital (DFNWC)		 125 234 170 89 51
Net Working Capital (NWC)		 125 234 170 89 51
Net Nonoperating Expense (NNE)		 11 22 36 32 30
Net Nonoperating Obligations (NNO)		 -129 -251 -204 -105 -61
Total Depreciation and Amortization (D&A)		 2.48 3.09 6.16 9.00 8.28
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - -
Adjusted Basic Earnings per Share		 $0.00 ($4.10) ($2.76) ($1.68) ($1.31)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 41.29M 44.82M 73.79M 84.82M
Adjusted Diluted Earnings per Share		 $0.00 ($4.10) ($2.76) ($1.68) ($1.31)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 41.29M 44.82M 73.79M 84.82M
Adjusted Basic & Diluted Earnings per Share		 $0.00 ($4.10) $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 17.73M 66.87M 78.52M 87.58M
Normalized Net Operating Profit after Tax (NOPAT)		 -27 -51 -88 -92 -81
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% -0.02% 0.00% -0.40% 0.00%

Quarterly Metrics And Ratios for Tenaya Therapeutics

This table displays calculated financial ratios and metrics derived from Tenaya Therapeutics' official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
DEI Shares Outstanding		 67,865,158.00 68,111,019.00 78,516,142.00 78,517,534.00 78,889,107.00 - 87,582,646.00 162,666,931.00 162,976,102.00 166,505,885.00
DEI Adjusted Shares Outstanding		 67,865,158.00 68,111,019.00 78,516,142.00 78,517,534.00 78,889,107.00 - 87,582,646.00 162,666,931.00 162,976,102.00 166,505,885.00
DEI Earnings Per Adjusted Shares Outstanding		 -0.43 -0.44 -0.41 -0.37 -0.32 - -0.31 -0.14 -0.12 -0.12
Growth Metrics		 - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 1.12% 16.09% 1.70% 14.49% 15.24% 17.21% 21.49% 23.86% 23.01% 26.22%
EBIT Growth		 1.19% 9.11% 0.09% 12.20% 13.60% 21.52% 18.35% 21.82% 21.64% 27.03%
NOPAT Growth		 1.21% 8.98% -0.12% 12.20% 13.61% 21.61% 18.43% 21.87% 21.62% 27.14%
Net Income Growth		 5.06% 10.68% -1.55% 11.54% 12.04% 20.37% 16.64% 20.89% 20.91% 28.26%
EPS Growth		 47.30% 29.31% 6.98% 24.44% 23.08% 34.15% 40.00% 58.82% 60.00% 62.50%
Operating Cash Flow Growth		 14.22% 3.34% 5.38% 9.93% 16.08% 16.13% 19.36% 33.89% 21.36% 16.78%
Free Cash Flow Firm Growth		 74.69% 51.12% 33.48% 9.79% -30.67% 21.34% 18.01% 42.55% 46.38% 44.39%
Invested Capital Growth		 -21.58% -11.15% -13.99% -9.41% -9.88% -9.70% -13.06% -18.83% -19.85% -19.00%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 13.02% 5.21% -14.75% 9.62% 13.78% 7.42% -8.81% 12.34% 12.82% 0.00%
EBIT Q/Q Growth		 11.93% -1.57% -7.24% 8.48% 13.33% 7.73% -11.57% 12.37% 13.13% 0.00%
NOPAT Q/Q Growth		 11.92% -1.70% -7.37% 8.71% 13.34% 7.71% -11.71% 12.55% 13.06% 0.00%
Net Income Q/Q Growth		 12.40% -2.72% -7.66% 8.68% 12.90% 7.01% -12.70% 13.33% 12.92% 0.00%
EPS Q/Q Growth		 13.33% -5.13% 2.44% 15.00% 11.76% 10.00% 11.11% 41.67% 14.29% 0.00%
Operating Cash Flow Q/Q Growth		 9.85% 7.25% -30.72% 17.60% 16.01% 7.30% -25.69% 32.45% 0.09% 0.00%
Free Cash Flow Firm Q/Q Growth		 42.12% -53.06% -0.79% -1.03% 16.16% 7.86% -5.05% 29.21% 21.76% 0.00%
Invested Capital Q/Q Growth		 -4.01% -5.39% 3.30% -3.44% -4.50% -5.21% -0.54% -9.85% -5.70% 0.00%
Profitability Metrics		 - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 100.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -8,134.22%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -8,917.78%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -8,917.78%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -8,565.33%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 94.26% 95.32% 95.69% 95.48% 95.96% 96.71% 97.69% 96.62% 96.86% 96.05%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -70.69% -64.83% -66.69% -74.54% -84.49% -95.69% -76.21% -85.21% -96.44% 0.00%
Cash Return on Invested Capital (CROIC)		 -200.60% -236.64% -221.38% -233.61% -235.46% -235.05% -214.72% -208.59% -205.96% 21.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -70.69% -64.83% -66.69% -74.54% -84.49% -95.69% -76.21% -85.21% -96.44% 0.00%
Return on Equity Simple (ROE_SIMPLE)		 -77.43% 0.00% -78.76% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -22 -22 -24 -22 -19 -17 -19 -17 -15 -14
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -6,242.44%
Net Nonoperating Expense Percent (NNEP)		 -5.40% -5.13% -5.81% -6.26% -6.68% -7.92% -7.21% -7.52% -8.28% -6.18%
Return On Investment Capital (ROIC_SIMPLE)		 - -15.79% -14.94% -16.10% -16.61% -18.58% -16.15% -16.89% -17.69% -13.23%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 2,420.89%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 6,596.89%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 9,017.78%
Earnings before Interest and Taxes (EBIT)		 -31 -31 -34 -31 -27 -25 -27 -24 -21 -20
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -29 -28 -32 -29 -25 -23 -25 -22 -19 -18
Valuation Ratios		 - - - - - - - - - -
Price to Book Value (P/BV)		 1.05 1.58 2.60 1.82 1.35 1.22 0.42 1.00 3.19 1.09
Price to Tangible Book Value (P/TBV)		 1.05 1.58 2.60 1.82 1.35 1.22 0.42 1.00 3.19 1.09
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 1.22 3.34 8.03 4.15 2.20 1.65 0.00 0.99 7.82 1.36
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 5.80
Leverage & Solvency		 - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -0.77 -0.81 -0.79 -0.77 -0.75 -0.72 -0.76 -0.73 -0.69 -0.75
Leverage Ratio		 1.16 1.17 1.15 1.19 1.20 1.25 1.18 1.22 1.26 1.24
Compound Leverage Factor		 1.10 1.12 1.10 1.13 1.15 1.21 1.16 1.18 1.22 1.19
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 1.08 0.97 6.03 1.04 -1.66 -3.66 -4.00 -3.83 -0.74 -3.86
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - -
Current Ratio		 6.55 4.91 6.72 6.28 5.27 4.22 6.68 6.00 4.64 5.75
Quick Ratio		 6.28 4.60 6.38 5.94 4.91 3.85 6.23 5.66 4.26 5.45
Cash Flow Metrics		 - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -12 -18 -18 -18 -15 -14 -15 -10 -8.08 -8.11
Operating Cash Flow to CapEx		 -295,475.00% -5,564.47% -5,081.56% -32,352.05% -10,780.43% -9,013.73% -6,034.46% -10,995.07% -59,996.15% -174,854.55%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - -
Invested Capital		 37 35 36 35 33 31 31 28 27 25
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 -10 -4.36 -5.85 -3.61 -3.63 -3.37 -4.69 -6.53 -6.58 -5.94
Enterprise Value (EV)		 45 116 288 144 73 52 -38 28 208 34
Market Capitalization		 173 221 411 243 152 113 50 99 264 115
Book Value per Share		 $2.43 $2.05 $2.01 $1.71 $1.43 $1.17 $1.36 $0.61 $0.51 $0.49
Tangible Book Value per Share		 $2.43 $2.05 $2.01 $1.71 $1.43 $1.17 $1.36 $0.61 $0.51 $0.49
Total Capital		 165 139 158 134 113 93 119 100 83 106
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -128 -105 -122 -99 -79 -61 -88 -72 -56 -81
Capital Expenditures (CapEx)		 0.01 0.39 0.56 0.07 0.18 0.20 0.38 0.14 0.03 0.01
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -14 -16 -13 -11 -10 -10 -7.83 -8.45 -8.28 -1.11
Debt-free Net Working Capital (DFNWC)		 107 89 110 88 69 51 80 63 48 80
Net Working Capital (NWC)		 107 89 110 88 69 51 80 63 48 80
Net Nonoperating Expense (NNE)		 7.50 7.92 8.59 7.85 6.94 6.58 7.59 6.43 5.62 5.23
Net Nonoperating Obligations (NNO)		 -128 -105 -122 -99 -79 -61 -88 -72 -56 -81
Total Depreciation and Amortization (D&A)		 1.87 3.87 2.08 2.27 2.09 1.85 2.69 2.35 1.98 1.76
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.39) ($0.41) ($0.40) ($0.34) ($0.30) ($0.27) ($0.24) ($0.14) ($0.12) ($0.09)
Adjusted Weighted Average Basic Shares Outstanding		 73.92M 73.79M 80.98M 85.71M 86.16M 84.82M 109.87M 162.79M 163.35M 216.88M
Adjusted Diluted Earnings per Share		 ($0.39) ($0.41) ($0.40) ($0.34) ($0.30) ($0.27) ($0.24) ($0.14) ($0.12) ($0.09)
Adjusted Weighted Average Diluted Shares Outstanding		 73.92M 73.79M 80.98M 85.71M 86.16M 84.82M 109.87M 162.79M 163.35M 216.88M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 68.11M 78.52M 78.52M 78.89M 79.22M 87.58M 162.67M 162.98M 166.51M 217.00M
Normalized Net Operating Profit after Tax (NOPAT)		 -22 -22 -24 -22 -19 -17 -19 -17 -15 -14
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -6,242.44%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -8,565.33%
Debt Service Ratios		 - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 -0.39% -0.40% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Tenaya Therapeutics (NASDAQ: TNYA) remains a pre-revenue biotech with significant cash on hand, but it continues to burn cash at a high rate as it advances its pipeline. The latest quarter shows a stronger balance sheet than earlier in 2025, largely because of capital raised, but operating losses are still substantial.

  • Cash position improved sharply versus late 2025: Tenaya ended Q1 2026 with $80.9 million in cash and equivalents, up from $56.3 million at Q3 2025.
  • Total assets increased: Assets rose to $135.1 million in Q1 2026 from $105.0 million in Q3 2025, reflecting a stronger liquidity position.
  • Debt remains absent: The balance sheet does not show interest-bearing debt, which reduces financial risk.
  • Equity base expanded: Total common equity increased to $106.2 million in Q1 2026 from $82.9 million in Q3 2025.
  • Operating cash outflow improved slightly year over year: Net cash used in operations was $19.2 million in Q1 2026, down from $23.1 million in Q1 2025.
  • Revenue is still minimal: Q1 2026 revenue was only $225,000, so the company is still far from meaningful commercial scale.
  • Interest income helps offset losses: Q1 2026 included $793,000 of interest and investment income, but this is not enough to cover operating expenses.
  • Accounts receivable and deferred revenue are present: The company continues to report some collaboration-related balance sheet items, but they are not large enough to materially change the story.
  • Operating losses remain large: Q1 2026 operating loss was $20.1 million, only modestly better than the $20.9 million loss in Q3 2025.
  • Net loss remained sizable: Tenaya reported a Q1 2026 net loss of $19.3 million, or $(0.09) per share.
  • Cash burn is still high: The company used $19.7 million of cash in Q1 2026, which means it will likely need additional capital if losses continue at this pace.
  • R&D spending remains the main expense driver: Research and development expense was $14.8 million in Q1 2026, reflecting continued pipeline investment without offsetting product revenue.
  • Share count has been rising over time: Weighted average basic shares in Q1 2026 were 216.9 million, well above the 109.9 million reported in Q1 2025, suggesting meaningful dilution from financing activity.

Bottom line: Tenaya Therapeutics has improved liquidity and is sitting on a healthier cash position than it had in late 2025, but the business still generates little revenue and burns cash quickly. For retail investors, the key question remains whether upcoming clinical and pipeline milestones can justify the ongoing dilution and cash usage.

07/05/26 02:50 PM ETAI Generated. May Contain Errors.

Tenaya Therapeutics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Tenaya Therapeutics' fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

Tenaya Therapeutics' net income appears to be on an upward trend, with a most recent value of -$111.13 million in 2024, rising from -$38.40 million in 2020. The previous period was -$124.08 million in 2023. Check out Tenaya Therapeutics' forecast to explore projected trends and price targets.

Tenaya Therapeutics' total operating income in 2024 was -$115.95 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $115.95 million

Over the last 4 years, Tenaya Therapeutics' total revenue changed from $0.00 in 2020 to $0.00 in 2024, a change of 0.0%.

Tenaya Therapeutics' total liabilities were at $23.66 million at the end of 2025, a 12.7% decrease from 2024, and a 171.2% increase since 2020.

In the past 5 years, Tenaya Therapeutics' cash and equivalents has ranged from $4.32 million in 2024 to $128.54 million in 2020, and is currently $100.55 million as of their latest financial filing in 2025.

Over the last 4 years, Tenaya Therapeutics' book value per share changed from -83.65 in 2020 to 1.17 in 2024, a change of -101.4%.


Related Companies

Financial statements for NASDAQ:TNYA last updated on 7/2/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Do NOT Buy SpaceX – Do This Instead
SpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...
Stansberry Research | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
Trump just signed it
A recent policy development is drawing attention from income-focused investors. According to one analyst, c...
Investors Alley | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
From the man who predicted 2008 crash…
Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...
Porter & Company | Sponsoredtc pixel